PURPOSE: The aim of this study was to determine the frequency of endometriosis in epithelial ovarian cancer patients. METHODS: Patients who had undergone epithelial ovarian cancer surgery between 2000 and 2004 were subjected to a retrospective analysis. The analysis focused on the presence of ovarian endometriosis, histological types and stages of ovarian cancer, treatment types and five-year survival rate. RESULTS: Out of the 210 operated ovarian cancer patients, 23 had coexisting ovarian endometriosis. Ovarian endometriosis was detected in 3.5% (4 of 113 patients) of cases with serous ovarian cancer, in 31.6% (12 of 38 patients) of cases with endometrioid, and in 36.8% (7 of 19 patients) of cases with clear cell ovarian cancer. The treatment of ovarian cancer patients was a combination of surgery and chemotherapy. CONCLUSION: Endometriosis was most frequently present in patients with clear cell (36.8%) and endometrioid ovarian cancers (31.6%). The five-year survival rate for ovarian cancer patients in all stages was 39.1%.
PURPOSE: The aim of this study was to determine the frequency of endometriosis in epithelial ovarian cancerpatients. METHODS:Patients who had undergone epithelial ovarian cancer surgery between 2000 and 2004 were subjected to a retrospective analysis. The analysis focused on the presence of ovarian endometriosis, histological types and stages of ovarian cancer, treatment types and five-year survival rate. RESULTS: Out of the 210 operated ovarian cancerpatients, 23 had coexisting ovarian endometriosis. Ovarian endometriosis was detected in 3.5% (4 of 113 patients) of cases with serous ovarian cancer, in 31.6% (12 of 38 patients) of cases with endometrioid, and in 36.8% (7 of 19 patients) of cases with clear cell ovarian cancer. The treatment of ovarian cancerpatients was a combination of surgery and chemotherapy. CONCLUSION: Endometriosis was most frequently present in patients with clear cell (36.8%) and endometrioid ovarian cancers (31.6%). The five-year survival rate for ovarian cancerpatients in all stages was 39.1%.
Authors: Alexis D Greene; Stephanie A Lang; Jessica A Kendziorski; Julie M Sroga-Rios; Thomas J Herzog; Katherine A Burns Journal: Reproduction Date: 2016-05-10 Impact factor: 3.906
Authors: Simon G Coetzee; Howard C Shen; Dennis J Hazelett; Kate Lawrenson; Karoline Kuchenbaecker; Jonathan Tyrer; Suhn K Rhie; Keren Levanon; Alison Karst; Ronny Drapkin; Susan J Ramus; Fergus J Couch; Kenneth Offit; Georgia Chenevix-Trench; Alvaro N A Monteiro; Antonis Antoniou; Matthew Freedman; Gerhard A Coetzee; Paul D P Pharoah; Houtan Noushmehr; Simon A Gayther Journal: Hum Mol Genet Date: 2015-03-24 Impact factor: 6.150
Authors: Doerthe Brueggmann; Claire Templeman; Anna Starzinski-Powitz; Nagesh P Rao; Simon A Gayther; Kate Lawrenson Journal: J Ovarian Res Date: 2014-02-06 Impact factor: 4.234